目的 探討參松養(yǎng)心膠囊聯(lián)合瑞舒伐他汀對(duì)急性心肌梗死后心臟功能和早期心室重構(gòu)的影響。方法 選取2016年1月—2018年2月漢中市中心醫(yī)院進(jìn)行診治的急性心肌梗死患者88例作為研究對(duì)象，根據(jù)治療方法的不同將患者分為對(duì)照組（40例）和觀察組（48例）。對(duì)照組口服瑞舒伐他汀鈣片，20 mg，1次/d。觀察組在對(duì)照組基礎(chǔ)上口服參松養(yǎng)心膠囊，4粒/次，3次/d。兩組均治療觀察3個(gè)月。觀察兩組患者的臨床療效，同時(shí)比較兩組患者的心功能指標(biāo)、心室重構(gòu)情況和主要心血管事件發(fā)生情況。結(jié)果 治療后，觀察組與對(duì)照組的總有效率分別為97.9%和87.5%，兩組患者總有效率比較差異顯著（P<0.05）。兩組治療后的左心室射血分?jǐn)?shù)（LVEF）、左心室舒張期內(nèi)徑（LVDd）和左心室收縮期內(nèi)徑（LVDs）值顯著高于治療前（P<0.05），且觀察組心功能指標(biāo)水平明顯高于對(duì)照組（P<0.05）。治療后，觀察組患者正性重構(gòu)、無(wú)重構(gòu)與負(fù)性重構(gòu)例數(shù)分別為2例、18例與28例，而對(duì)照組分別為18例、10例、12例，對(duì)比差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后隨訪6個(gè)月，觀察組的主要心血管事件的發(fā)生率為8.3%，顯著低于對(duì)照組的32.5%（P<0.05）。結(jié)論 參松養(yǎng)心膠囊聯(lián)合瑞舒伐他汀治療急性心肌梗死后能改善早期心室重構(gòu)狀況和心臟功能，從而提高患者的近遠(yuǎn)期療效。

Objective To investigate the effects of Shensong Yangxin Capsules combined with rosuvastatin on cardiac function and early ventricular remodeling after acute myocardial infarction. Methods A total of 88 patients with acute myocardial infarction treated in Hanzhong Central Hospital from January 2016 to February 2018 were selected as research objects, and the patients were divided into control group (40 cases) and observation group (48 cases) according to different treatment methods. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 20 mg, once daily. Patients in the observation group were po administered with Shensong Yangxin Capsules on the basis of control group, 4 capsules/time, three times daily. Both groups were treated and observed for 3 months. The clinical efficacy in two groups was observed, and the cardiac function indicators, ventricular remodeling, and major cardiovascular events in two groups were compared. Results After treatment, the total effective rate of the observation group and the control group was 97.9% and 87.5%, respectively, with significant difference between the two groups (P<0.05). After treatment, the values of LVEF, LVDd, and LVDs in two groups were significantly higher than those before treatment (P<0.05), and the level of cardiac function indexes in the observation group was significantly higher than those in the control group (P<0.05). After treatment, the number of positive, non-reconstructive, and negative reconstructive patients in the observation group was 2, 18, and 28 cases, respectively, while those in the control group was 18, 10, and 12 cases, respectively, with statistically significant difference (P<0.05). After 6 months of follow-up, the incidence of major cardiovascular events in the observation group was 8.3%, significantly lower than 32.5% in the control group (P<0.05). Conclusion Shensong Yangxin Capsules combined with rosuvastatin in treatment of acute myocardial infarction can improve the early stage of ventricular remodeling and cardiac function, so as to improve the s efficacy of patients.

R972